ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO World Congress on Gastrointestinal Cancer

 

30 June - 3 July 2021 Virtual Conference
Close
N. Poster
Poster title
Applicant name
Status
  SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey Joanne Franklin Received Received
  PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress) Natalie Pizzimenti Received Received
  P-1 Health-related quality of life of rectal cancer survivors treated with curative intent André Ferreira Received Received
  P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis Sik Kwan Chan Received Received
  PD-2 Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer Richard Kim Received Received
  SO-3 Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe Julien Taieb Received Received
  PD-3 Impact of RAS status, prior targeted therapy, age, and gender on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: Real-world data from the QoLiTrap study Roger von Moos Received Received
  P-3 Gastric cancer: 10-year survival Oleg Kshivets Received Received
  P-4 Prognostic and therapeutic values of tumor-infiltrating lymphocytes in localized colon cancer sonia Ben Nasr Received Received
  O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium Corinna Slawinski Received Received
  SO-4 Progression-free survival in patients With cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response Ghassan Abou-Alfa Received Received
  LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer Zev Wainberg Received Received
  PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet bevacizumab Riccardo Giampieri Received Received
  SO-5 Tumor inflammation and proliferative status as biomarkers in gastroesophageal adenocarcinoma Sarbajit Mukherjee Received Received
  P-5 The use of complementary and alternative medicine among colorectal cancer patients in Tunisia sonia Ben Nasr Received Received
  O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial Naoki Izawa Received Received
  P-6 Spatio-temporal distribution pattern of pancreatic cancer mortality rate in Peru between 2003-2017 Claudio Flores Received Received
  PD-6 Prediction of patients at high risk of upper gastrointestinal cancer for endoscopy using artificial intelligent technology Yiguang Lin Received Received
  SO-6 Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer: Results from the UK MRC OE02 trial Maximilian Kloft Received Received
  O-7 FOLFIRI napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study Manish A. Shah Received Received
  P-7 How much can GIT cancer patients afford for effective and safe treatment? Rasha Aboelhassan Received Received
  SO-7 The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database Lei Deng Received Received
  P-8 Nutritional status among colorectal cancer patients in Tunisia sonia Ben Nasr Received Received
  P-9 Prognostic role of preoperative inflammation parameters in predicting postoperative complications of colorectal cancer surgery. sonia Ben Nasr Received Received
  SO-9 Analysis of the immune-related endpoints of the mismatch repairdeficient non-endometrial solid cancers cohort from the GARNET study Thierry André Received Received
  SO-10 An open-label, multi-centre, phase Ib/II study of PI3K ive inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway Minkyu Jung Received Received
  P-10 Prevalence and risk factors of chronic neuropathy in 225 colorectal cancer patients treated with oxaliplatin-based regimens in Tunisia sonia Ben Nasr Received Received
  P-11 GAME score in patients with liver metastases from colorectal cancer Wala Ben Kridis Received Received
  O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan Hiromichi Shirasu Received Received
  P-12 Long intergenic non-protein coding RNA 1094 regulates the progression of gastric cancer Ouyang Ge Received Received
  O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study Lisa Salvatore Received Received
  P-13 Efficacy of FOLFOX4 regimen with advanced hepatocellular carcinoma and prognostic factors for survival Chawalit Chayangsu Received Received
  SO-13 KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients Emerik Osterlund Received Received
  O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08) Yu Sunakawa Received Received
  P-14 The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with pancreatic cancer bengueddach aicha Received Received
  O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma Kohei Shitara Received Received
  SO-14 The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study Yuki Matsubara Received Received
  SO-15 Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study Gabor Liposits Received Received
  P-15 Diagnostic potential of erythrocyte and serum fatty acids in spotting adenomatous polyps and identifying the early stages of colorectal cancer depending on tumor localization Margarita Kruchinina Received Received
  P-16 How does reinduction of first-line chemotherapy in patients with metastatic colorectal cancer impact outcomes? Experience from the University Hospital for Tumors, Zagreb, Croatia Mirjana Pavlovic Received Received
  SO-16 Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595) Pia Osterlund Received Received
  P-17 CT colonography: A minimally invasive screening option for colorectal cancer Jagmeet Grewal Received Received
  SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study Julien Taieb Received Received
  P-18 Phase Ib study of niraparib plus tebotelimab in patients with advanced or metastatic gastric cancer after prior treatment failure Bo Lyu Received Received
  SO-19 A multicenter phase II trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial Naoki Izawa Received Received
  P-19 Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Treatment of Intra-hepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial Stephen Lam Chan Received Received
  SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study. Carlotta Antoniotti Received Received
  P-20 Concurrent chemo-radiotherapy in anal squamous cell carcinomas: A 10-year retrospective review of a tertiary centre experience Abdelfattah Elmasry Received Received
  SO-21 Impact of timing of perioperative chemotherapy on survival outcomes among patients with colorectal liver metastases: A propensity score matching of the national cancer database Firas Baidoun Received Received
  P-21 Real-world outcomes in patients with advanced or metastatic gastric adenocarcinoma in the United States Daniel Beachler Received Received
  P-22 Role of timing to laparoscopic or robotic surgery after neoadjuvant chemoradiotherapy for rectal cancer: The TiMiSNAR trial Igor Monsellato Received Received
  SO-23 The genomic temporal heterogeneity of circulating tumor DNA in metastatic colorectal cancer under first-line treatment Feng Wang Received Received
  P-23 Experience of concurrent chemoradiotherapy for pancreatic cancer in a large university hospital Gemma Searle Received Received
  P-24 A prospective phase 1b dose de-escalation open-label clinical study to evaluate the safety and efficacy of sorafenib with metformin and atorvastatin in advanced hepatocellular carcinoma (SMASH) PRABHAT BHARGAVA Received Received
  SO-24 Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study Paolo Manca Received Received
  SO-25 Global rise in early-onset colorectal cancer: An association with antibiotic consumption? Sarah Perrott Received Received
  P-25 A review of circulating exosomal biomarkers in the diagnosis of pancreatic cancer Menazir Sha Received Received
  SO-26 In-silico Lynch syndrome-related neoantigens prediction for a dendritic cell-based cancer prevention vaccine Cristina Bayó Received Received
  P-27 The efficacy and safety of XELOX/SOX plus bevacizumab as neoadjuvant chemotherapy for locally advanced rectal cancer compared with XELOX/SOX: A retrospective study Nanako Sakaguchi Received Received
  SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib cetuximab /- binimetinib in BEACON CRC Michele Springer Received Received
  P-28 Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study yui okada Received Received
  SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: an expanded dataset Valentina Boni Received Received
  P-29 Pancreatic cancer during the COVID-19 pandemic: A high-volume Polish centre experience Karolina K&281;dzierska-Kapuza Received Received
  SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study Ali Shamseddine Received Received
  SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer Hyun Cheol Chung Received Received
  P-31 Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies Nieves Martinez Lago Received Received
  P-32 SARS-CoV-2 pandemic and delayed presentation of gastrointestinal cancer patients: A retrospective evaluation and the impact on clinical outcome Budhi Ida Bagus Received Received
  P-33 Results of initial DPYD screening for cancer patients receiving fluoropyrimidines Matilde Bolaños Received Received
  P-34 Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors Nieves Martinez Lago Received Received
  P-35 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment. Ken Ito Received Received
  P-37 SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress) Tanios Bekaii-Saab Received Received
  P-38 Unmet needs and concerns of Russian patients with CRC: Analysis of Russian internet postings Aleksandr Krotkevich Received Received
  P-39 The role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib Margherita Rimini Received Received
  P-40 Lenvatinib versus sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study Margherita Rimini Received Received
  P-42 Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorectal cancer: A retrospective cohort study Gerardo Rosati Received Received
  P-43 C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in mestizo patients with metastatic colorectal cancer. Allan Ramos-Esquivel Received Received
  P-44 Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma Wanpeng Wang Received Received
  P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer Kanwal Raghav Received Received
  P-46 Integrated transcriptomics and the exploration of cancer-promoting genes CDKN3 in esophageal squamous cell cancer Yan Pan Received Received
  P-47 5-fluorouracil bolus use in infusional regimens among oncologists: A survey by Brazilian Group of Gastrointestinal Tumors RENATA PEIXOTO Received Received
  P-48 Study of paclitaxel and ramucirumab as second-line therapy after failure of FOLFOX-6 regimen in metastatic stomach carcinoma patients Varun Goel Received Received
  P-49 Oesophageal neuroendocrine carcinoma: retrospective evaluation of outcomes from a UK tertiary centre Michael Tilby Received Received
  P-50 Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study Esther Álvarez-García Received Received
  P-51 Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients Erika Martinelli Received Received
  P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location Stefan Kasper Received Received
  P-53 Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis Rachel Broadbent Received Received
  P-54 Higher muscle mass is associated with better response to concurrent neoadjuvant chemoradiotherapy in rectal cancer patients Kiril Zhelev Received Received
  P-55 Constructing a Hybrid Control for the MORPHEUS Colorectal Cancer (CRC) Trial Using IMblaze370 Historical Trial Data Neil Segal Received Received
  P-56 A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR) Hiroyuki Takeda Received Received
  P-57 US real-world ramucirumab and immune checkpoint inhibitor (ICI) treatment sequences in advanced gastric, gastroesophageal junction, or esophageal cancer. Julie Beyrer Received Received
  P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria BERING CRC Frank Reichenbach Received Received
  P-60 Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy Juan Luis Sanz Received Received
  P-61 Relatlimab nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073 Kathryn Woods Received Received
  P-62 Overall survival of patients with pancreatic cancer Claudio Flores Received Received
  P-63 MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - randomised, double-blind, placebo-controlled, Phase 3 study Yelena Yuriy Janjigian Received Received
  P-64 The?impact of?sarcopenia?on overall survival?among?cholangiocarcinoma patients: A systematic review?and meta-analysis Jeannette Tandiono Received Received
  P-65 Expression of TIMP-1 level as a diagnostic and prognostic factor in colon cancer patients: A systematic review Jeannette Tandiono Received Received
  P-66 Experience in our center of bone events not related to the disease in patients with locally advanced or metastatic adenocarcinoma of the pancreas INMACULADA GALLEGO JIMENEZ Received Received
  P-67 Prognostic implication of HER2 overexpression in surgically treated patients with gastric cancer Erkhembayar Enkhbat Received Received
  P-68 Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting Clara Garcia Grove Received Received
  P-69 Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience. Alessandro Rizzo Received Received
  P-70 First-in-human study of highly ive FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors Cori Ann Sherwin Received Received
  P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation Josep Tabernero Received Received
  P-72 A Patient Preference Study on Risk Thresholds to Switch Between Daily Tablets and Biweekly Infusions in Second-Line Treatment for Advanced Hepatocellular Carcinoma Neehar Parikh Received Received
  P-73 The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study Floriana Camarda Received Received
  P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study Maria Grazia Maratta Received Received
  P-75 Impact of an educational activity on the knowledge of oncologists regarding the latest clinical trial data on HER2-directed therapies for gastric and colorectal cancer Nabil Dorkhom Received Received
  P-76 Effect of educational activity on the knowledge of oncologists regarding the latest clinical trial data investigating immunotherapy combination regimens for the frontline treatment of patients with unresectable HCC Nabil Dorkhom Received Received
  P-78 Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib Jasmine Huynh Received Received
  P-79 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody Ken Ito Received Received
  P-80 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON Open Health Open Health Received Received
  P-81 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment Ken Ito Received Received
  P-82 Impact of type 2 diabetes mellitus in overall survival and clinical features of Latin patients with colorectal cancer: A 15-year follow-up German Calderillo Received Received
  P-83 The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1 Koshi Kumagai Received Received
  P-84 Genotype-fenotype correlation in patients with Lynch syndrome and colorectal cancer Jose Angel García-Cuesta Received Received
  P-85 Relationship between microsatellite instability and neoadjuvant chemotherapy response in gastric or gastroesophageal junction cancer: A meta-analysis Selin Akturk Esen Received Received
  P-86 The importance of sphingosine kinase 1 isoform expression in the gut-liver axis Hongjie Chen Received Received
  P-87 Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study Mariana Sardinha Received Received
  P-89 The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma Feng Bi Received Received
  P-90 Combined high expression of MAP17 and fascin-1 in colorectal cancer: Targeted therapy in need? Athanasios Tampakis Received Received
  P-91 Safety and efficacy of perioperative FLOT in elderly patients: Real-world data Mafalda Baleiras Received Received
  P-92 The neuroendocrine tumor diagnostic process and the role of gastrointestinal specialists Simone Leyden Received Received
  P-93 The characteristics and prognosis of extragastrointestinal stromal tumors: A single center retrospective analysis of 31 patients Mingchun Mu Received Received
  P-94 Unicentric real-world data from esophageal cancer neoadjuvant treatment according to the CROSS trial protocol Joana Mendona Received Received
  P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers Kei Muro Received Received
  P-96 Analysis of three biographical times of disease in the IMbrave 150 study: A new measure to assess clinical effect Eduardo Ceballos Barbancho Received Received
  P-97 Updated results of HGCSG1603: a phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer Michio Nakamura Received Received
  P-98 A single-arm study of apatinib plus neoadjuvant chemotherapy followed by resection in patients with locally advanced colorectal adenocarcinoma Aimin Zhang Received Received
  P-99 Circulating RNA detection, circulating tumor cells count (CTC) and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials Susana Rodríguez Received Received
  P-100 A phase II study of first-line chemotherapy initiating FOLFIRIcetuximab and switching to FOLFIRIbevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial Hirokazu Shoji Received Received
  P-101 Survival of early-onset gastric signet ring cell carcinoma in the Korean population between 2010 and 2015: Analysis of the Korean central cancer registry database Hee Man Kim Received Received
  P-102 The importance of maintenance chemotherapy in the first and second lines of treatment of metastatic colorectal cancer Danila Gridnev Received Received
  P-103 Associations between quality-of-life, symptom burden, and demographic characteristics in long-term esophageal and gastroesophageal junction cancer survivors Erin McGillivray Received Received
  P-104 Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy Stefan de Vogel Received Received
  P-105 POLO: patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer Hedy Kindler Received Received
  P-106 Descriptive study of long-term survivors with advanced pancreatic cancer Victoria Aviño Tarazona Received Received
  P-107 Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib Anisha Patel Received Received
  P-108 Circulating tumor DNA for early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma Maen Abdelrahim Received Received
  P-109 CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge) for post-chemo-radiotherapy surveillance in patients with oesophageal cancer a feasibility study Somnath Mukherjee Received Received
  P-110 Is dexamethasone necessary as a prophylactic antiemetic prior to gemcitabine plus nab-paclitaxel therapy? Shiho Murata Received Received
  P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification Syneos Health Received Received
  P-112 Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: the VHIO experience stefania napoli Received Received
  P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement Ulita Nonemaker Received Received
  P-114 Claudin 18 isoform expression in gastric adenocarcinoma and pancreatic adenocarcinoma Takeshi Saito Received Received
  P-116 What have we learned about of trifluridine/tipiracil (TAS-102)? Real World Data at four GEODA hospitals (Spain) JULIA MARTÍNEZ PÉREZ Received Received
  P-117 Survival Outcomes following Systemic Chemotherapy in Stage IVA/B High-grade Mucinous Appendiceal Cancer after Unsuccessful Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Ekaterina Baron Received Received
  P-118 Survival Outcomes of Adjuvant Chemotherapy in Stage IVA/B High-grade Appendiceal Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Ekaterina Baron Received Received
  P-119 Impact of circulating tumor DNA on clinical decisions in the adjuvant setting in patients with colorectal cancer Vanessa Wookey Received Received
  P-120 Pre-assessment tool predicting complication following oesophagogastric resection: Sarcopenia or incremental shuttle walk test Yashashwi Sinha Received Received
  P-121 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study Mikhail Fedyannin Received Received
  P-122 Gastrointestinal side effects of morphine in cancer pain: A comparison between the smoking and non-smoking patients Fatima Zahra Hijri Received Received
  P-123 Survival analysis based on the grade of neutropenia in patients with metastatic colorectal cancer treated with trifluridine-tipiracil Victoria Aviño Tarazona Received Received
  P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma Yung-Yeh Su Received Received
  P-125 Caring for more than survival: A survey of patient preferences in advanced hepatocellular carcinoma Siu Hing Lo Received Received
  P-126 Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load Chiun Hsu Received Received
  P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy Andrea Pretta Received Received
  P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus Andrea Pretta Received Received
  P-129 Concomitant RAS and BRAF mutations: impact on overall survival and progression free survival in metastatic colorectal cancer patients Andrea Pretta Received Received
  P-130 Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study Niklaus Schaefer Received Received
  P-131 External validation of prognostic ALAN score in patients with inoperable bile duct cancer treated with second-line chemotherapy Riccardo Giampieri Received Received
  P-132 Molecular profiling of KIT and PDGFRA in Chilean GIST patients: A Latin-American perspective Matias Muñoz-Medel Received Received
  P-133 The watch-and-wait approach in stage IV rectal cancer patients: A good alternative for TME surgery? Petra Custers Received Received
  P-134 Social determinants of health are risk factors for early onset colorectal cancer in Appalachia William Oelsner Received Received
  P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress Daneng Li Received Received
  P-136 Detecting panitumumab/FOLFOX responders in K-Ras wild-type metastatic colorectal cancer through an artificial intelligence-based analytical tool Carlos Galmarini Received Received
  P-137 Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer Miriam Koopman Received Received
  P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) /- chemotherapy in first-line therapy of advanced/metastatic HER2 gastroesophageal junction or gastric cancer Daniel Catenacci Received Received
  P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated ed solid tumors: Pancreatic cancer cohort Hyun Cheol Chung Received Received
  P-140 A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers Hi-Jen Tsai Received Received
  P-141 Neoadjuvant chemotherapy with docetaxel, nedaplatin, and 5-FU for resectable esophageal cancer: A single center retrospective study Satoko Shindo Received Received
  P-142 Safety and efficacy of apatinib for non-surgical advanced esophageal cancer: A real-world study Hongfei Zhang Received Received
  P-143 Polyphyllin ? and resiquimod-loaded injectable hydrogels promote the polarization of tumor-associated macrophages and enhance gastric cancer immunotherapy Hanqing Qian Received Received
  P-144 A comparative analysis of secondary data from the ToGA and EVIDENCE studies on the effectiveness of trastuzumab plus chemotherapy in Asian patients with HER2 metastatic gastric cancer Ying Wu Received Received
  P-145 Doublet regimen plus anti-vascular endothelial growth factor drug regimen after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer Toshihiko Matsumoto Received Received
  P-146 Clinical usefulness of next generation sequencing by liquid biopsy for advanced gastric cancer Toshihiko Matsumoto Received Received
  P-147 Epigenetic gene somatic mutations in gastric cancer Alexey Kalinkin Received Received
  P-148 Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling Cristina Morelli Received Received
  P-149 Integrative analysis of the genomic and transcriptomic landscape identifies novel key genes as a therapeutic target in bile duct cancer Massimiliano Salati Received Received
  P-150 Insights into the gastric and oesophageal cancer patient experience: Results of a pan-European patient survey Zorana Maravic Received Received
  P-151 The prognostic value of TCF1CD8T cell in primary small cell carcinoma of the esophagus Lin Ma Received Received
  P-152 Sarcopenia in advanced colorectal cancer patients treated with trifluridine/tipiracil Mateusz Malik Received Received
  P-153 Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center Zara Vidales Sepulveda Received Received
  P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 Josep Tabernero Received Received
  P-155 A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis Kazuhiro Shiraishi Received Received
  P-156 A European chart review of treatment patterns and outcomes for patients with resected esophageal cancer or gastroesophageal junction cancer Prianka Singh Received Received
  P-157 Assessing fitness for systemic therapy in hepatocellular carcinoma: Evaluating time on treatment according to Child-Pugh classification, model for end-stage liver disease score, and AFP level Benjamin Staum Received Received
  P-158 Deciphering the immunological determinants of response to neoadjuvant chemo-radiation in esophageal adenocarcinoma Giuseppina Arbore Received Received
  P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction Rita Laeufle Received Received
  P-160 Young Latin American population with colorectal cancer: Characteristics of bad prognosis German Calderillo Received Received
  P-161 The diagnostic methods for detection of Helicobacter pylori infection: A comparative approach to invasive methods. Fabian Castro-Valencia Received Received
  P-162 Universally adopted Vitamin D deficiency cutoff of 10 ng/mL is optimal for metastatic colorectal cancer prognostication and corrleated with neutrophil/lymphocyte ratio michela rofei Received Received
  P-163 Real-world outcomes of cisplatin, capecitabine and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma Nadia Hitchen Received Received
  P-164 MONEO: A phase II study of avelumab plus FLOT in the peri-operative treatment for patients with resectable gastric or gastroesophageal junction cancer Maria Alsina Received Received
  P-165 Comparative study on the clinical effect of hand-assisted laparoscopic and laparoscopic gastrectomy for gastric stromal tumor Qu-xia Zhang Received Received
  P-166 Operative versus nonoperative treatment for stage 0 rectal cancer following chemoradiation therapy Fatima Aurora Aires Received Received
  P-167 Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients Binyi Xiao Received Received
  P-168 Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study Vilma Pacheco-Barcia Received Received
  P-169 Tumor-infiltrating lymphocytes in colorectal cancer: A clinical outcome predictor Marina Vitorino Received Received
  P-170 Assessment of long-term outcomes and predictive factors of malignancy in branch-duct intraductal papillary mucinous neoplasms: A retrospective study in a Canadian referral center Anas Chennouf Received Received
  P-171 Does metastasectomy really improve survival in gastric cancer? Marcelle Cesca Received Received
  P-172 PTHrP and SPARC expressions in human colorectal cancer: An in silico analysis Pedro Matías Carriere Received Received
  P-173 Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Final results of an observational study Myrto Kastrisiou Received Received
  P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2 gastric or gastroesophageal junction adenocarcinoma: Trial in progress Natalie Pizzimenti Received Received
  P-175 Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors Martín Igor Gómez-Randulfe Rodríguez Received Received
  P-176 A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04) Vaibhav Sahai Received Received
  P-177 Early onset colorectal cancer outcomes in a public Uruguayan cancer centre Santiago Fontes Received Received
  P-178 Rego-Nivo for the treatment of HCC refractory to chemotherapy after the 2nd line yasmina ben merabet Received Received
  P-180 Rectal cancer in the elderly: Characteristics, management and outcomes from a single centre retrospective cohort review Ruba A Hamed Received Received
  P-181 Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer (SOAP trial) SUWA YUSUKE Received Received
  P-182 A multicenter study of prognostic factors in nivolumab monotherapy for advanced or recurrent esophageal cancer Tatsuki Ikoma Received Received
  P-183 Laparoscopic colorectal resection for elderly patients aged 80 years or older: A propensity score analysis Ryo Inada Received Received
  P-184 Underlining mechanism for the efficacy of tumor treating fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma Adi Haber Received Received
  P-185 A prospective, randomized, controlled, multicenter phase III clinical trial of apatinib combined with neoadjuvant chemoradiotherapy for patients with locally advanced, HER2-negative, Siewerts type II-III adenocarcinoma of esophagogastric junction Qun Zhao Received Received
  P-186 Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in biliary tract cancer patients Sung Yong Han Received Received
  P-187 Watch-and-wait strategy for DNA mismatch repair-deficient/microsatellite instability-high rectal cancer with a clinical complete response after neoadjuvant immunotherapy: An observational cohort study Qiao-xuan Wang Received Received
  P-188 Propensity score analysis of outcomes following laparoscopic or open radical resection for gallbladder carcinoma in T2 and T3 stages changwei dou Received Received
  P-189 Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort Ayano Sakai Received Received
  P-190 Exploring possible predictors of survival in hepatocellular carcinoma Ins Eiriz Received Received
  P-191 Prognostic factors of colorectal cancer liver metastasectomy Ins Costa Received Received
  P-192 Chemoradiation for anal canal carcinoma: A multicentric retrospective cohort study Ines Leao Received Received
  P-193 Final results of hepatectomy followed by adjuvant chemotherapy with 3-month capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase 2 study Hiroki Hashida Received Received
  P-194 Study of efficacy and safety of combination of octreotide acetate LAR with lenvatinib as second-line therapy in patients with advanced G1-G2 NETs of non-pancreatic origin varun goel Received Received
  P-195 Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients Jean Paul NSHIZIRUNGU Received Received
  P-196 Frequency, biological behaviour and survival nomograms discrimination in non-KIT mutated gastrointestinal stromal tumors Tiago Alpoim Received Received
  P-197 The influence of proton pump inhibitor utilization on the pathological response of rectal cancer: A multicenter study by the Sociedad Latino Americana de Oncologia Gastrointestinal (SLAGO) Marcelle Cesca Received Received
  P-198 Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy CLAUDIA CARDONE Received Received
  P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy Davide Ciardiello Received Received
  P-200 A phase II study of dose reductive XELOX plus bevacizumab in elderly or vulnerable patients with metastatic colorectal cancer: MCSGO-1202 Ken Nakata Received Received
  P-201 Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors Marcelle Cesca Received Received
  P-202 Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer Joana Marinho Received Received
  P-203 Relationship of myelotoxicity and of gastrointestinal toxicity with the treatment outcome in trials of second-line chemotherapy of patients with metastatic colorectal cancer Antonella Venturino Received Received
  P-204 Survival improvement from the addition of biologics is not affected by performance status in patients with metastatic colorectal cancer: A meta-analysis Giuseppe Colloca Received Received
  P-206 Survival comparison of first-line therapies in locally advanced or metastatic pancreatic cancer: A Portuguese oncology unit experience Rita Gameiro-dos-Santos Received Received
  P-207 FLOT in clinical practice: Retrospective analysis of an oncological center Raquel Fontes Received Received
  P-208 Pancreatic neuroendocrine neoplasia: Experience of a comprehensive cancer center Sara Coelho Received Received
  P-209 Cancers of the bile duct: A study of 30 cases benamar wassila Received Received
  P-210 Capecitabine and temozolomide for metastatic neuroendocrine neoplasms: A single-center real-word data analysis Ana Caetano Received Received
  P-211 Risk of diabetes in subjects with positive fecal immunochemical test: A nationwide population-based study Hyun Jung Lee Received Received
  P-212 The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinoma Ruijingfang Jiang Received Received
  P-213 Helicobacter pylori babA gene evolution and adaptation in Colombian populations Kevin Guzman Received Received
  P-214 Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study Nikolaos Tsoukalas Received Received
  P-215 Short-term results and survival outcomes following resection of localized pancreatic neuroendocrine tumors: a brazilian single center experience. Dante Arra Received Received
  P-216 Gender-specific genomic alterations among Hispanic patients with metastatic colorectal cancer Sayed Reshad Ghafouri Received Received
  P-217 The knowledge and awareness for colorectal cancer in advanced colorectal cancer patients in China: A national multicenter study HUIFANG XU Received Received
  P-218 STAT3 signaling inhibition in regulatory T cells improves immune response to RT in PDAC Miles Piper Received Received
  P-219 Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study Cagatay Arslan Received Received
  P-221 Repurposing disulfiram as treatment for metastatic colorectal cancer: An investigator-initiated clinical phase I/II trial Line Tarpgaard Received Received
  P-222 Dihydropyrimidine dehydrogenase deficiencies and fluoropyrimidine toxicities: A study in the Tunisian Center Melliti Rihab Received Received
  P-223 Gasdermin B predicts good prognosis and more macrophage infiltration liang Sun Received Received
  P-224 Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study Anastasia Kottorou Received Received
  P-225 Clinico-epidemiological and therapeutic profile of rectal cancer: Experience of the department of radiation oncology EHSO ORAN meriem cheriguene Received Received
  P-226 Trifluridin/tipiracil and regorafenib sequencing in Slovenian patients with metastatic colorectal cancer Tanja Mesti Received Received
  P-227 Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis Zhaolun Cai Received Received
  P-228 Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease Anna Virgili Received Received
  P-229 Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma Julien Edeline Received Received
  P-230 Is stereotactic microwave ablation of resectable colorectal liver metastasis an alternative for liver resection in the Covid-19 pandemic? Thiery Chapelle Received Received
  P-231 Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis Hannah Christina Puhr Received Received
  P-232 Prognostic inflammatory and microRNA biomarkers in stage IV colorectal cancer patients Sally Temraz Received Received
  P-233 Patient information and management by eHealth intervention during colon cancer Melina Campagnaro Received Received
  P-234 Participation of screening and barriers in Chinese patients with advanced colorectal cancer before diagnosis: A national multi-center cross-sectional study Yin Liu Received Received
  P-235 E-health monitoring during pancreatic cancer treatment Melina Campagnaro Received Received
  P-237 Clinical doctors attitudes towards colorectal cancer genetic testing: A national multi-center cross-sectional study Yin Liu Received Received
  P-238 Clinicopathological profile and prognostic factors impacting survival of periampullary carcinoma: A tertiary care centre experience ADITYA KUMAR SINGLA Received Received
  P-239 Consensus molecular subtypes of morphological regions on colorectal tumors Vlad Popovici Received Received
  P-240 The diagnosis and treatment of advanced colorectal cancer in China: A national multi-center cross-sectional study HUIFANG XU Received Received
  P-243 A prospective study to assess the impact of colostomy on psychosocial aspects of quality of life in colorectal cancer patients Divya Khosla Received Received
  P-244 Role of preoperative contrast-enhanced computed tomography in staging of gastric cancer in patients undergoing upfront surgery with curative intent Lalchhandami Colney Received Received
  P-245 Evaluation of colon-specific plasma nanovesicles as new markers of colorectal cancer Inga Nazarova Received Received
  P-250 Epidemiological, diagnostic and therapeutic profile of pancreatic cancer: Experience of a medical oncology department Somia Chaibdra Tani Received Received
  P-252 Residual fibrosis after treatment with anti-epidermal growth factor receptor or bevacizumab in colorectal liver metastases and its correlation with survival: A retrospective pooled analysis Xavier Hernández-Yage Received Received
  P-253 Detection of potential molecules that might be implicated in colorectal metastasis to lung Panagiotis Apostolou Received Received
  P-255 The clinical significance of the gut microbiota in RAS wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies in combination with chemotherapy - preliminary results Pawe&322; Stelmasiak Received Received
  P-256 Fibroblast-induced paradoxical PI3K pathway activation in colorectal cancer: Role of PTEN and potential implications for PI3K/mTOR inhibition Chiara Bazzichetto Received Received
  P-258 Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer Size Chen Received Received
  P-261 Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma Sarina Piha-Paul Received Received
  P-262 Highly sensitive quantification of Extracellular Vesicles Derived From Colorectal Cancer Nadezhda Nikiforova Received Received
  P-263 The effects of co-administration of erlotinib and apatinib in the treatment oesophageal squamous cell carcinoma Yiguang Lin Received Received
  P-264 Helicobacter pylori SNPs associated with tetracycline, clarithromycin and amoxicillin resistance in Colombia Kevin Guzman Received Received
  P-265 Neoadjuvant radiotherapy for locally advanced rectal cancer during the first wave of COVID19 pandemic: Guys cancer cohort experience Kasia Owczarczyk Received Received
  P-266 Oncological outcomes of self-expanding metal stents as a bridge to surgery for obstructive left-sided colon cancer Laura Gomez Fernandez Received Received
  P-267 Interleukin-8 levels as a predictor of colorectal cancer patient prognosis Fabiana Conciatori Received Received
  P-268 Seaweed laminaria japonica peptides possess strong anti-liver cancer effects Hongjie Chen Received Received
  P-269 Advanced gastric cancer bleeding: Association of hemostatic radiotherapy and iron supplementation - Is there a survival benefit? André Laranja Received Received
  P-270 Impact of intestinal stoma on quality of life in Tunisian patients with colorectal cancer NOUHA AMMAR Received Received
  P-271 The anti-tumor effect of Curcuma phaeocaulis cyclopeptide in human hepatoma HepG2 cells Hongjie Chen Received Received
  P-272 Significance of adding oxaliplatin to postoperative adjuvant chemotherapy in elderly patients with colorectal cancer Yusuke Nagata Received Received
  P-273 Mucinous colorectal cancer in Tunisian patients: A controversial clinicopathological type Haifa TOUNSI GUETTITI Received Received
  P-274 Exploratory analysis of potential clinical, molecular and analytical prognostic factors of real-world patients with gastrointestinal stromal tumors: A single center study Ignacio Perez Criado Received Received
  P-275 Evaluation of radical chemoradiation outcomes in stage II/III anal cancer: Real-world data population Isabel Fernandes Received Received
  P-278 Checkpoint Inhibitors in Patients with Advanced, Refractory Biliary Tract Cancers Savannah Liddell Received Received
  P-279 Thromboembolic complications in colorectal cancers nassima mkedder Received Received
  P-280 HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma Robert Merker Received Received
  P-281 Low proliferation indexes in colorectal cancer in Tunisian patients: Association with rectal localization, mucinous histological type and stage Dorra Wider Received Received
  P-282 Factors predicting response to neoadjuvant chemotherapy in gastric cancer Pavan Kumar C G Received Received
  P-283 Prognostic factors in the evaluation of stage II/III squamous cell carcinoma of the anus treated with chemoradiation João Gramaa Received Received
  P-284 Exploratory magnetic resonance imaging histogram biomarkers for response prediction to neoadjuvant treatment in oesophageal/gastro-oesophageal cancer Kasia Owczarczyk Received Received
  P-285 Treatment outcomes with sorafenib in advanced hepatocellular carcinoma: A single-center retrospective study Juraj Prejac Received Received
  P-286 Assessment of the quality of life of patients with colorectal cancer in the Tunisian Center: A report of 142 patients Imtinene Belaid Received Received
  P-287 Preclinical evaluation of alpelisib (PI3K inhibitor ) and its synergistic effect in combination with ribociclib (CDK 4/6 inhibitor) in colorectal cancer razia aslam Received Received
  P-288 Individual drug-screening and heterogeneity analyses of patient-derived tumoroids: A roadmap to improving therapy in pancreatic cancer Christine Nitschke Received Received
  P-289 Gastric and esophageal signet ring cell adenocarcinoma: A retrospective analysis of outcomes at Mayo Clinic Zhubene Mesbah Received Received
  P-290 Mutant allele specific imbalance in RAS as prognostic marker in colorectal cancer Nirit Yarom Received Received
  P-291 The prognostic and predictive factors for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Banu Ozturk Received Received
  P-292 Tumor downstaging as an associated factor with recurrence of disease in patients with operated rectal cancer after neoadjuvant chemoradiotherapy: Real-world data from Peru Rodrigo Motta Received Received
  P-294 Impact of surgical margin status on the survival outcome after surgical resection of gastric cancer: A systematic review and meta-analysis Zhiyuan Jiang Received Received
  P-295 The importance of sphingosine kinase 1 isoform expression in the gut-liver axis Hongjie Chen Received Received
  P-296 Establishment of adoptive cell therapy with tumor-infiltrating lymphocytes for liver and oesophageal cancer Shuzhi Ma Received Received
  P-297 Upfront dihydropyrimidine dehydrogenase deficiency detection to secure 5-FU or capecitabine administration: Application to colorectal cancer patients nassima mkedder Received Received
  LBA-298 Response to Total Neoadjuvant Therapy and Survival in Patients with Early Onset Locally Advanced Rectal Cancer Melissa Lumish Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
02:46
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

ESMO World Congress on Gastrointestinal Cancer

 

30 June - 3 July 2021 Virtual Conference
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 30/04/2021 TO 30/06/2022
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert